KR102288022B1 - 건성 안 질환 치료용 안구 조성물 - Google Patents

건성 안 질환 치료용 안구 조성물 Download PDF

Info

Publication number
KR102288022B1
KR102288022B1 KR1020197021384A KR20197021384A KR102288022B1 KR 102288022 B1 KR102288022 B1 KR 102288022B1 KR 1020197021384 A KR1020197021384 A KR 1020197021384A KR 20197021384 A KR20197021384 A KR 20197021384A KR 102288022 B1 KR102288022 B1 KR 102288022B1
Authority
KR
South Korea
Prior art keywords
composition
cyclosporine
dry eye
ethanol
perfluorobutyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197021384A
Other languages
English (en)
Korean (ko)
Other versions
KR20190100283A (ko
Inventor
마르쿠스 베이어
외르그 헤이져
알리스 메이데스
손자 크로저
하르트무트 포스
프랭크 로쉐
베른하르트 귄터
Original Assignee
노바리크 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노바리크 게엠베하 filed Critical 노바리크 게엠베하
Publication of KR20190100283A publication Critical patent/KR20190100283A/ko
Application granted granted Critical
Publication of KR102288022B1 publication Critical patent/KR102288022B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A61J1/1468—Containers characterised by specific material properties
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
    • A61J1/06—Ampoules or carpules
    • A61J1/067—Flexible ampoules, the contents of which are expelled by squeezing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020197021384A 2016-12-23 2017-12-20 건성 안 질환 치료용 안구 조성물 Active KR102288022B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP16206735 2016-12-23
EP16206735.9 2016-12-23
EP17165578.0 2017-04-07
EP17165578 2017-04-07
PCT/EP2017/083770 WO2018115097A1 (en) 2016-12-23 2017-12-20 Ophthalmic composition for treatment of dry eye disease

Publications (2)

Publication Number Publication Date
KR20190100283A KR20190100283A (ko) 2019-08-28
KR102288022B1 true KR102288022B1 (ko) 2021-08-10

Family

ID=61002978

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197021384A Active KR102288022B1 (ko) 2016-12-23 2017-12-20 건성 안 질환 치료용 안구 조성물

Country Status (14)

Country Link
US (1) US20180360908A1 (enExample)
EP (3) EP3777830B1 (enExample)
JP (2) JP7032404B2 (enExample)
KR (1) KR102288022B1 (enExample)
CN (1) CN110267645A (enExample)
AU (1) AU2017384650B2 (enExample)
BR (1) BR112019012791A2 (enExample)
CA (1) CA3045743C (enExample)
DK (1) DK3399962T3 (enExample)
ES (2) ES2965883T3 (enExample)
MX (1) MX381639B (enExample)
PL (1) PL3399962T3 (enExample)
PT (1) PT3399962T (enExample)
WO (1) WO2018115097A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012023421B1 (pt) 2010-03-17 2021-09-14 Novaliq Gmbh Composição farmacêutica para tratamento de aumento de pressão intraocular
EP2444063A1 (en) 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
CA3142049C (en) 2012-09-12 2023-08-29 Novaliq Gmbh Semifluorinated alkane compositions
CA2997744C (en) 2012-09-12 2019-12-31 Novaliq Gmbh Compositions comprising mixtures of semifluorinated alkanes
CA2918419C (en) 2013-07-23 2022-05-03 Novaliq Gmbh Stabilized antibody compositions
WO2017055454A1 (en) 2015-09-30 2017-04-06 Novaliq Gmbh Semifluorinated compounds and their compositions
DK3356313T3 (da) 2015-09-30 2020-07-20 Novaliq Gmbh 2-perfluorhexyloktan til oftalmisk indgivelse
JP2019520357A (ja) 2016-06-23 2019-07-18 ノバリック ゲーエムベーハー 局所投与方法
WO2018054932A1 (en) 2016-09-22 2018-03-29 Novaliq Gmbh Pharmaceutical compositions for use in the therapy of blepharitis
CN109906085B (zh) 2016-09-23 2024-03-08 诺瓦利克有限责任公司 含有环孢素的眼用组合物
PL3612228T3 (pl) 2017-04-21 2024-04-08 Dermaliq Therapeutics, Inc. Kompozycje jodu
US11278503B2 (en) 2017-05-12 2022-03-22 Novaliq Gmbh Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions
SG11202002640YA (en) 2017-09-27 2020-04-29 Novaliq Gmbh Ophthalmic compositions comprising latanoprost for use in the treatment of ocular diseases
US11896559B2 (en) 2017-10-04 2024-02-13 Novaliq Gmbh Opthalmic compositions comprising F6H8
CA3091308A1 (en) 2018-03-02 2019-09-06 Novaliq Gmbh Pharmaceutical compositions comprising nebivolol
WO2019206956A1 (en) 2018-04-27 2019-10-31 Novaliq Gmbh Ophthalmic compositions comprising tafluprost for the treatment of glaucoma
US12472162B2 (en) * 2018-07-24 2025-11-18 Carefusion 213, Llc Ready-to-use, terminally sterile packaging for surgical antiseptic and method of use
MY206642A (en) * 2018-10-12 2024-12-30 Novaliq Gmbh Ophthalmic composition for treatment of dry eye disease
US12397039B2 (en) 2019-02-13 2025-08-26 Novaliq Gmbh Compositions and methods for the treatment of ocular neovascularization
US20220226426A1 (en) * 2019-05-24 2022-07-21 Novaliq Gmbh Ophthalmic composition for the treatment of ocular allergy
AU2020340561A1 (en) * 2019-09-06 2022-03-31 Novaliq Gmbh Ophthalmic composition for the treatment of uveitis
EP3861857A1 (en) * 2020-02-07 2021-08-11 Novaliq GmbH Antiparasitic compositions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2335735A1 (en) * 2009-12-14 2011-06-22 Novaliq GmbH Pharmaceutical composition for treatment of dry eye syndrome
WO2013126602A1 (en) * 2012-02-21 2013-08-29 Massachusetts Eye & Ear Infirmary Inflammatory eye disorders
US9878000B2 (en) * 2012-06-20 2018-01-30 University Of Waterloo Mucoadhesive nanoparticle composition comprising immunosuppresant and methods of use thereof
CA2997744C (en) * 2012-09-12 2019-12-31 Novaliq Gmbh Compositions comprising mixtures of semifluorinated alkanes
KR20150095684A (ko) * 2012-12-18 2015-08-21 노파르티스 아게 히알루로난에 결합하는 펩티드 태그를 이용하는 조성물 및 방법
CN106572941B (zh) * 2014-08-13 2020-06-23 佛罗里达大学研究基金会股份有限公司 从眼药水中去除防腐剂

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Investigative Ophthalmology & Visual Science, Vol.56(7), 319. doi(2015년)

Also Published As

Publication number Publication date
ES2965883T3 (es) 2024-04-17
US20230043641A1 (en) 2023-02-09
MX381639B (es) 2025-03-13
PT3399962T (pt) 2020-09-03
EP3777830A1 (en) 2021-02-17
PL3399962T3 (pl) 2021-02-08
EP3399962B1 (en) 2020-06-10
BR112019012791A2 (pt) 2019-12-03
AU2017384650A1 (en) 2019-07-04
MX2019007587A (es) 2019-12-16
AU2017384650B2 (en) 2021-02-18
CA3045743C (en) 2023-08-29
EP3777830B1 (en) 2023-11-29
EP3399962A1 (en) 2018-11-14
JP7032404B2 (ja) 2022-03-08
WO2018115097A9 (en) 2018-08-23
EP3777830C0 (en) 2023-11-29
JP2020502197A (ja) 2020-01-23
US20180360908A1 (en) 2018-12-20
DK3399962T3 (da) 2020-09-07
WO2018115097A1 (en) 2018-06-28
JP2022050514A (ja) 2022-03-30
CN110267645A (zh) 2019-09-20
ES2819005T3 (es) 2021-04-14
EP4374851A3 (en) 2024-08-21
EP4374851A2 (en) 2024-05-29
KR20190100283A (ko) 2019-08-28
CA3045743A1 (en) 2018-06-28

Similar Documents

Publication Publication Date Title
KR102288022B1 (ko) 건성 안 질환 치료용 안구 조성물
US12059449B2 (en) Ophthalmic composition for treatment of dry eye disease
RS59636B1 (sr) Kompozicije i postupci za nehirurško lečenje ptoze
AU2020281641B2 (en) Ophthalmic composition for the treatment of ocular allergy
US12496326B2 (en) Ophthalmic composition for treatment of dry eye disease
HK40113015A (en) Ophthalmic composition for treatment of dry eye disease
RU2828769C2 (ru) Офтальмологические композиции для лечения синдрома сухого глаза
HK40000392B (en) Ophthalmic composition for treatment of dry eye disease
HK40000392A (en) Ophthalmic composition for treatment of dry eye disease
HK40114301A (en) Ophthalmic composition for treatment of dry eye disease
HK40058504B (en) Ophthalmic composition for treatment of dry eye disease
HK40058504A (en) Ophthalmic composition for treatment of dry eye disease

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190722

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200522

Comment text: Request for Examination of Application

PA0302 Request for accelerated examination

Patent event date: 20200522

Patent event code: PA03022R01D

Comment text: Request for Accelerated Examination

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20200910

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20210210

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20200910

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20210210

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20210111

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20200522

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20210611

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20210517

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20210210

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20210111

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20200522

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20210804

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20210804

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20240725

Start annual number: 4

End annual number: 4